CASK
MGP Ingredients, Inc.
CASK's outlook is improving, though it still trails on the overall score.
CELH
Celsius Holdings, Inc.
CELH has the edge over CASK overall, supported by stronger fundamentals and stronger valuation.
CASK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Weak |
CASK's revenue, profitability, cash flow and balance sheet are all currently under pressure.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CASK PE Valuation
CASK has no meaningful PE right now: it lost money over the past year.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
CASK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CASK's earnings to grow and its profitability to improve, with its revenue holding steady.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over CASK on the outlook, with more favorable revenue expectations.
CASK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.72 | — |
| Q3 2026 | -$11.66 | -$11.04 |
| Q2 2026 | -$11.27 | -$11.01 |
| Q1 2026 | -$11.15 | -2330% |
| Q4 2025 | -$4.99 | -420% |
| Q3 2025 | -$0.62 | -113% |
| Q2 2025 | -$0.26 | -106% |
| Q1 2025 | $0.50 | -88% |
| Q4 2024 | $1.56 | -68% |
CASK lost $11.66 per share over the past year, and its loss has widened in each of the last eight quarters.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH has the edge over CASK on earnings quality, reporting a profit while its opponent remains loss making.
CASK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $117.9M | -9.9% |
| Q2 2026 | $124.4M | -15% |
| Q1 2026 | $106.4M | -13% |
| Q4 2025 | $138.3M | -23% |
| Q3 2025 | $130.9M | -19% |
| Q2 2025 | $145.5M | -24% |
| Q1 2025 | $121.7M | -29% |
| Q4 2024 | $180.8M | -16% |
CASK's revenue has slid since its 2023 peak: $118M last quarter, down 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -5.9 points |
| Q2 2026 | 14% | +0.2 points |
| Q1 2026 | -163% | -162 points |
| Q4 2025 | -98% | -81 points |
| Q3 2025 | 16% | -4.1 points |
| Q2 2025 | 14% | -8.8 points |
| Q1 2025 | -0.6% | -18 points |
| Q4 2024 | -17% | -37 points |
CASK's operating margin was 10% last quarter, down 5.9 points from the same quarter a year ago.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over CASK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over CASK on profitability, with a higher operating margin.
CASK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $27.2M | -1.3% |
| Q2 2026 | -$52.2M | -$51.6M |
| Q1 2026 | $1.2M | -95% |
| Q4 2025 | $24.3M | +133% |
| Q3 2025 | $27.6M | +13% |
| Q2 2025 | -$557K | +$855K |
| Q1 2025 | $24.8M | +$27.2M |
| Q4 2024 | $10.4M | -53% |
CASK generated $527,000 in free cash flow over the past year, down 99% from the year before.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
CASK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24.9K shares |
| 1 year | +0.4% | +84.6K shares |
| 3 years | -4.1% | -924K shares |
| 5 years | -2.4% | -523K shares |
| Available history | +26% | +4.4M shares |
CASK has 21M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $35,000 |
| Q2 2026 | — |
| Q1 2026 | $886,000 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $1M |
| Q4 2024 | $36.5M |
CASK spent $921,000 buying back its own shares over the past year, down 98% from the year before.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over CASK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
CASK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 7.6x | High |
| Q2 2025 | 6.3x | High |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 3.1x | Elevated |
| Q3 2024 | 1.6x | Healthy |
| Q2 2024 | 1.8x | Healthy |
| Q1 2024 | 1.8x | Healthy |
| Q4 2023 | 1.6x | Healthy |
CASK's net debt is about 7.6 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has more cash than debt.
CASK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 72.8 | Neutral |
CASK's weekly RSI is 50 (neutral) and its Stochastic is 73 (neutral).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
CASK PE vs Consumer Defensive Sector
| Metric | CASK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 19x | — |
CASK has no meaningful PE right now: it lost money over the past year.
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
CASK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.3 | 11% above |
| 20 week MA | $16.2 | 4.7% above |
| 50 week MA | $19.1 | 11% below |
| 100 week MA | $24.5 | 31% below |
| 200 week MA | $56.8 | 70% below |
CASK has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 70% below its 200-week average.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
CASK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.9 | $47.4 | -3.1% |
| 2021 | $47.4 | $86.8 | +83% |
| 2022 | $86.8 | $109.4 | +26% |
| 2023 | $109.4 | $98.5 | -10% |
| 2024 | $98.5 | $39.5 | -60% |
| 2025 | $39.5 | $24.2 | -39% |
| 2026 YTD | $24.2 | $17.0 | -30% |
CASK has the edge over CELH on returns for 2026, with the stronger performance.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.